Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination
Kasum Azim1
Andrea Domenico Rivera2
Arthur Morgan Butt3
1.Department of Neurology,Medical Faculty, Heinrich-Heine-University,Düsseldorf,Germany2.Institute of Biomedical and Biomolecular Sciences,School of Pharmacy and Biomedical Science, University of Portsmouth,St Michael's Building,White Swan Road,Portsmouth,UK;Section of Human Anatomy,Department of Neuroscience,University of Padua,Padua,Italy3.Institute of Biomedical and Biomolecular Sciences,School of Pharmacy and Biomedical Science, University of Portsmouth,St Michael's Building,White Swan Road,Portsmouth,UK
摘要：The need for new therapeutic approaches: Conventional drug discovery is a lengthy and expensive process, taking decades and billions of dollars to get a drug from bench to bedside. Much of the costs incurred are at the pre-clinical stages, between drug design and synthesis to delineating the cellular "Mechanisms of Action" (MoA). Notably, there is a very high risk of failure, and only a very small proportion of therapeutic agents reach later-phase clinical trials. Accordingly, drug repositioning has become a valuable strategy aimed at fast-tracking treatments into clinical use and improving the chances of therapeutic success. A novel addition to this approach is connectivity mapping, which defines cell-specific transcriptional responses to small molecules in disease-dependent contexts. This commentary outlines how some of the latest innovations in connectivity mapping can be exploited for drug repurposing.
机标关键词：generationmappingagentsnextacquiringconnectivitydifferentiallydrug
论文发表日期：2023-04-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 797-798 )